DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for myofascial pain syndrome — screening already-approved drugs against its 11-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMyofascial pain syndrome maps to a 11-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for myofascial pain syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
sodium voltage-gated channel alpha subunit 9 (SCN9A) — SCN9A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7W9K · 2.2 Å · ligand O-[(R)-{[(2R)-2,3-bis(octadecanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine (P5S). Experimental structure, not a prediction.
What the evidence adds up to
In a 2024 rat study, platelet-derived growth factor receptor-α (PDGFR-α) phosphorylation was elevated in myofascial trigger point tissue taken by needle biopsy from the trapezius muscles of patients with myofascial pain syndrome, and the level of phosphorylation correlated positively with pain intensity. In the rats, activating PDGFR-α produced pain-like behaviours and muscle contraction through the Janus kinase 2/signal transducer and activator of transcription-3 (JAK2/STAT3) pathway. Inhibitors of JAK2/STAT3 reversed those pain-like behaviours and the muscle contraction. Collagen type I α 1 (COL1A1) was identified as a binding protein that promotes PDGFR-α phosphorylation and thereby contributes to pain-like behaviours and muscle contraction. These findings are from an animal model only; no human treatment data are reported.
A 1959 paper describes the management of myofascial pain syndromes but provides no original data on drug efficacy or patient outcomes. A 2010 paper states that myofascial pain syndrome is a non-specific lesion of skeletal muscles with trigger points and that biocontrolled mechanokinesitherapy is a promising drug-free treatment, but gives no patient numbers or response rates. A 2006 summary reports that in failed back surgery cases where other conservative and operative procedures had failed, needling and infiltration of trigger points followed by a multidisciplinary programme including heat, electric stimulation, relaxation and stretching exercises was a safe and effective approach in a high percentage of cases. No specific response rates, sample sizes, or controlled comparisons are provided.
No drug has been tested in a randomised controlled trial for myofascial pain syndrome in the abstracts supplied. The 2024 study identifies a molecular pathway but has not progressed to human trials. What is missing is funding for a clinical trial, a trial design that accounts for the heterogeneity of trigger point pathology, and patient stratification by pain duration or muscle group.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Anesthesiology · 2024 · 9 citations · open access
Platelet-derived Growth Factor Receptor-α Induces Contraction Knots and Inflammatory Pain–like Behavior in a Rat Model of Myofascial Trigger Points
AbstractBACKGROUND: Myofascial trigger points (MTrPs) are the primary etiological characteristics of chronic myofascial pain syndrome. Receptor tyrosine kinases (RTKs) are associated with signal transduction in the central mechanisms of chronic pain, but the role of RTKs in the peripheral mechanisms of MTrPs remains unclear. The current study aimed to identify RTKs expression in MTrPs and elucidate the molecular mechanisms through which platelet-derived growth factor receptor-α (PDGFR-α) induces contraction knots and inflammatory pain-like behavior in a rat model of myofascial trigger points. METHODS: MTrPs tissue samples were obtained from the trapezius muscles of patients with myofascial pain syndrome through needle biopsy, and PDGFR-α activation was analyzed by microarray, enzyme-linked immunosorbent assay, and histological staining. Sprague-Dawley rats (male and female) were used to investigate PDGFR-α signaling, assessing pain-like behaviors with Randall-Selitto and nest-building tests. Muscle fiber and sarcomere morphologies were observed using histology and electron microscopy. The PDGFR-α binding protein was identified by coimmunoprecipitation, liquid chromatograph mass spectrometer, and molecular docking. PDGFR-α-related protein or gene levels, muscle contraction, and inflammatory markers were determined by Western blot and reverse-transcription quantitative polymerase chain reaction. RESULTS: PDGFR-α phosphorylation levels were elevated in the MTrPs tissues of individuals with trapezius muscle pain and were positively correlated with pain intensity. In rats, PDGFR-α activation caused pain-like behaviors and muscle contraction via the Janus kinase 2/signal transducer and activator of transcription-3 (JAK2/STAT3) pathway. JAK2/STAT3 inhibitors reversed the pain-like behaviors and muscle contraction induced by PDGFR-α activation. Collagen type I α 1 (COL1A1) binds to PDGFR-α and promotes its phosphorylation, which contributed to pain-like behaviors and muscle contraction. CONCLUSIONS: COL1A1-induced phosphorylation of PDGFR-α and the subsequent activation of the JAK2/STAT3 pathway may induce dysfunctional muscle contraction and increased nociception at MTrPs.
AbstractJournal Article The Management of Myofascial Pain Syndromes Get access John J. Bonica, M.D. John J. Bonica, M.D. Director of the Departments of Anesthesiology, Tacoma General Hospital and Pierce County Hospital; and Clinical Associate Professor, Department of Anatomy, University of Washington Search for other works by this author on: Oxford Academic Google Scholar Physical Therapy, Volume 39, Issue 6, June 1959, Pages 389–396, https://doi.org/10.1093/ptj/39.6.389 Published: 01 June 1959
Russian Journal of Spine Surgery (Khirurgiya Pozvonochnika) · 2010 · 1 citations · open access
The Role of Myofascial Structuresin the Development of Pain Syndromes and Their Drug-Free Correction
AbstractMyofascial pain syndrome is a complex psychophysiological process determined by nonspecific lesion of skeletal muscles with formation of trigger points in tense muscles, which become generators of pathological reflex system. The role of myofascial structures in formation of a back pain syndrome was identified. It was shown that biocontrolled mechanokinesitherapy is a promising method of drug-free treatment for patients with myofascial pain syndrome.
Acupuncture & Electro-Therapeutics Research · 2006 · 0 citations
Efficacy of Myofascial Therapy in Failed Back Surgery
AbstractSummary Myofascial pain syndrome (MPS) plays an important role in the genesis of pain in failed back surgery. When other conservative and operative procedures had failed to give satisfactory results in failed back surgery, needling and infiltration of trigger points and tender spots followed by comprehensive multidisciplinary program proved to be a safe, low cost and very effective therapeutic approach in a high percentage of cases with chronic myofascial pain syndrome. The needling and infiltration was followed by physical therapy sessions including heat, electric stimulation, relaxation exercises, stretching exercises and correction of perpetuating and predisposing factors for MPS.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
